마이코플라스마 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Mycoplasma Diagnostics Market size is expected to reach USD 3.69 Billion in 2034 from USD 1.82 Billion (2025) growing at a CAGR of 8.17% during 2026-2034.

The Global Mycoplasma Diagnostics Market is witnessing growth due to increasing awareness about contamination risks in cell cultures and biopharmaceutical production. Mycoplasma infections can significantly impact research outcomes and product safety, driving demand for accurate diagnostic solutions. Growing biopharmaceutical manufacturing activities and cell therapy research are fueling market expansion. Technological advancements in PCR-based and rapid detection methods further enhance adoption rates.

Key drivers include rising R&D investments in biotechnology and stricter regulatory requirements for contamination control. The expansion of vaccine production and biologics manufacturing increases the need for reliable testing solutions. Growing laboratory automation and improvements in molecular diagnostic techniques support efficient detection processes. Additionally, the surge in cell-based research activities strengthens market demand globally.

Looking forward, advancements in rapid, real-time detection technologies will improve diagnostic efficiency. Integration of automation and digital data management systems will streamline laboratory workflows. Emerging markets are expected to offer growth opportunities due to expanding life sciences research infrastructure. As quality control becomes increasingly critical in biologics production, the mycoplasma diagnostics market is set for sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Techniques

• Polymerase Chain Reaction (PCR)
• Immunoassay
• Microbial Culture Techniques
• DNA Staining

By End User

• Hospitals
• Diagnostic Laboratories
• Clinics

COMPANIES PROFILED

• Agilent Technologies, American Type Culture Collection ATCC, Thermo Fisher Scientific Inc, Takara Holdings Inc, PromoCell GmbH, Merck KGaA, Lonza Group AG, Savyon Diagnostics Ltd, Tecan Group Ltd, Charles River Laboratories International, F HoffmannLa Roche AG, Sartorius Stedim Biotech SA
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET: BY TECHNIQUES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Techniques
• 4.2. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Microbial Culture Techniques Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. DNA Staining Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Techniques
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Techniques
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Techniques
  • 6.4.2 By End User
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Techniques
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Techniques
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MYCOPLASMA DIAGNOSTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Agilent Technologies
  • 8.2.2 American Type Culture Collection (ATCC)
  • 8.2.3 Thermo Fisher Scientific Inc
  • 8.2.4 Takara Holdings Inc
  • 8.2.5 PromoCell GmbH
  • 8.2.6 Merck KGaA
  • 8.2.7 Lonza Group AG
  • 8.2.8 Savyon Diagnostics Ltd
  • 8.2.9 Tecan Group Ltd
  • 8.2.10 Charles River Laboratories International
  • 8.2.11 F. Hoffmann-La Roche AG
  • 8.2.12 Sartorius Stedim Biotech S.A